BioLineRx logo

BioLineRx(NASDAQ) BLRX

Market Cap$11.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-98%
1 Year-38%
1 Month-16%
$2.32
-1.28%
-0.03Today
BioLineRx last closing stock price
MetricPriceDate
Last closeUSD 2.352026-09-30
BioLineRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.2%USD 2.562026-09-23
1 month-16.07%USD 2.802026-08-31
3 month-28.46%USD 3.292026-07-02
Year to date-15.16%USD 2.772025-12-31
1 year-37.83%USD 3.782025-09-30
3 year-96.77%USD 72.802023-09-29
5 year-97.89%USD 111.602021-10-01
Since inception-99.93%USD 3,354.002011-07-25

BioLineRx Financials at a Glance

Market Cap

$11.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.40M

Net Income (TTM)

-$8.03M

EPS (TTM)

-$1.82

P/E Ratio

-1.29

Dividend

$0.00

Beta (Volatility)

0.78 (Low)

Price

$2.32

Volume

5,811.345

Open

$2.32

Previous Close

$2.35

Daily Range

$2.32 - $2.39

52-Week Range

$2.15 - $4.56

Estimated Earnings Date

Nov 23, 2026

BLRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioLineRx

BioLineRx Ltd. is an Israeli biopharmaceutical company focused on developing innovative therapies primarily in oncology. Established in 2003, the company is advancing its clinical-stage pipeline, which includes promising candidates for various cancers and other serious conditions.

Products and Services
  • Motixafortide, targeting stem cell mobilization and pancreatic cancer
  • AGI-134, an immuno-oncology agent for solid tumors
  • BL-5010, a device for non-surgical skin lesion removal
Growth Outlook
  • Motixafortide is in Phase 2 studies for metastatic pancreatic adenocarcinoma
  • Strategic collaborations with MSD and MD Anderson Cancer Center enhance research capabilities
  • Pipeline expansion with AGI-134 and BL-5010 supports long-term growth potential
Financial Highlights
  • Q2 2026 revenue of $299,048, showing a focus on product development
  • Research and development expenses of $2,993,535 indicate strong investment in innovation
  • Cash and short-term investments totaled $13,077,905 as of June 30, 2026
BioLineRx Ltd. is positioned in the biotechnology sector, with a focus on oncology and innovative treatment solutions. The company's lead product, Motixafortide, has shown promise in clinical trials, particularly for stem cell mobilization and pancreatic cancer. The ongoing development of AGI-134 and BL-5010 further diversifies the pipeline, potentially addressing significant unmet medical needs. Recent financial data indicates a commitment to research and development, with substantial investments aimed at advancing clinical trials and expanding the product portfolio. The strategic partnerships with leading institutions enhance the company's research capabilities, positioning BioLineRx for future growth in the competitive biopharmaceutical landscape.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

24

CEO

Philip Adam Serlin, MBA, CPA

Website

www.biolinerx.com

Headquarters

Hevel Modi'in, HM 7177871, IL

BLRX Financials

Key Financial Metrics (TTM)

Gross Margin

69.98%

Operating Margin

-876.78%

Net Income Margin

-575.77%

Return on Equity

-47.22%

Return on Capital

-36.58%

Return on Assets

-24.17%

Earnings Yield

-77.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.98M

Volume

5.81K

Avg. Volume

19.33K

Financials (TTM)

Gross Profit

$976.26K

Operating Income

-$12.25M

EBITDA

-$8.26M

Operating Cash Flow

-$10.88M

Capital Expenditure

-$25.21K

Free Cash Flow

-$10.90M

Cash & ST Invst.

$13.08M

Total Debt

$7.94M

BioLineRx Performance Analysis

BioLineRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 4,787,631N/A
20242024-12-31USD 29,077,355507.3%
20252025-12-31USD 1,189,361-95.9%
BioLineRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3040.5%
Q42025-12-31-54.3%
Q12026-03-31144.4%
Q22026-06-30-37.3%
BioLineRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -19.27-21.4%
20232023-12-31USD -37.6595.4%
20242024-12-31USD -4.64-87.7%
20252025-12-31USD -0.29-93.7%
BioLineRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3077.9%
Q42025-12-31-44.9%
Q12026-03-31-81.7%
Q22026-06-30-20.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$299.05K

-1.6%

Gross Profit

$159.70K

-31.2%

Gross Margin

53.40%

N/A

Market Cap

$11.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$531.76K

N/A

Employees

22

N/A

Net Income

-$3.08M

+21.9%

EBITDA

-$3.56M

-1.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$13.08M

-53.6%

Total Debt

$7.94M

-37.0%

Accounts Receivable

$727.99K

+159.1%

Inventory

$2.17M

-24.0%

Long Term Debt

$3.18M

-58.8%

Short Term Debt

$4.76M

-2.6%

Return on Assets

-24.17%

N/A

Return on Invested Capital

-62.23%

N/A

Free Cash Flow

-$3.26M

-1739.2%

Operating Cash Flow

-$3.26M

-1742.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ICUSeaStar Medical Holding Corporation
$3.82-3.05%
AIMDAinos, Inc.
$1.31+2.76%
LNAILunai Bioworks Inc.
$1.45-1.70%
ADTXAditxt, Inc.
$0.00-10.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$32.77-0.94%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.69-0.24%
NUNu Holdings
$12.86+1.58%
NXLNexalin Technology
$7.85+83.39%

Questions About BLRX

What is the current price of BioLineRx?

BioLineRx is trading at $2.32 per share.

What is the 52-week range for BioLineRx?

Over the past 52 weeks, BioLineRx has traded between $2.15 and $4.56.

How much debt does BioLineRx have?

As of the most recent reporting period, BioLineRx reported total debt of $7.94M.

How much cash does BioLineRx have on hand?

BioLineRx reported $4.63M in cash and cash equivalents in its most recent financial results.

What is BioLineRx’s dividend yield?

BioLineRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services